Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12272899 | 0.78 | CASP3 (0.33) | IDH1CASP3 | |
| SCHEMBL12812986 | 0.73 | SNCA (0.47) | IDH1SNCACASP3 | |
| SCHEMBL12273414 | 0.70 | CRHR1 (0.31) | — | |
| SCHEMBL12272996 | 0.69 | PDE7B (0.31) | — | |
| SCHEMBL12273608 | 0.69 | MAPT (0.34) | — | |
| SCHEMBL12273537 | 0.69 | CASP3 (0.34) | IDH1CASP3 | |
| SCHEMBL5725873 | 0.68 | SNCA (0.41) | IDH1SNCACASP3 | |
| SCHEMBL12272985 | 0.67 | AR (0.33) | — | |
| SCHEMBL15948223 | 0.66 | CRHR1 (0.35) | IDH1SNCACASP3 | |
| SCHEMBL15948227 | 0.65 | SNCA (0.35) | IDH1SNCACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-8809317-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120302556-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012135402-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012125983-A1 | ANTIVIRAL TREATMENTS | PROSETTA ANTIVIRAL INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120238543-A1 | Antiviral Compounds | Prosetta Antiviral, Inc. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238543-A1 | Antiviral Compounds | MAVS, EIF2AK2, IRF3 | IDH1 333/4885SNCA 1190/4885CASP3 188/4885 |
| US-20120302556-A1 | Antiviral Compounds | HAVCR2, MAVS, EIF2AK2 | IDH1 1101/4885SNCA 734/4885CASP3 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.